98 results about "Sphingomyelin" patented technology

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.

Novel cyclic and acyclic oxazaphospholanes are described, as well as their use in the synthesis of sphingomyelin and sphingomyelin analogous. The production of synthetic sphingomyelins is also described. 2S, 3R stereoisomers of oxazaphospholanes and sphingomyelins, and synthetic methods for their preparation are described.

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The invention provides a serum metabolism marker for diagnosis of gestational diabetes mellitus and application of the serum metabolism marker. Specifically, sphingomyelin SM (8:0; 2O / 11:0) and oleoyl carnitine CAR (18:2) can serve as a biomarker of gestational diabetes mellitus, can be used for evaluating the disease risk of the gestational diabetes mellitus or diagnosing the gestational diabetes mellitus, and have the advantages of high accuracy and strong sensitivity, so that that the serum metabolism marker has an important clinical application value.

The present invention provides a method for long-term stabilization of inositol dehydrogenase, ketoamine oxidase and sphingomyelinase in liquid. The method is used to prepare an enzymatic biochemicalkit for determining inositol, glycated albumin and small and dense low density lipoprotein cholesterol for a purpose of enabling the enzymatic biochemical kit to have a shelf life of 12 months or more. The method is characterized in that a composition of 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether is added to a reagent solution for preserving enzymes, and concentrations of the 4-formylbenzeneboronic acid and benzyldimethylphenol polyoxyethylene ether are preferably 0.008-0.012 w / V% and 0.1-0.2 w / V%, respectively.

The invention belongs to the field of medicinal chemistry and relates to an alkoxy benzo five-membered (six-membered) heterocyclic amine compound shown by a formula I or a pharmaceutically acceptablesalt thereof and medicinal application thereof, wherein R1, R2 and R3 are consistent with the detailed description in the summary of the invention. The compound can selectively inhibit the activity ofsphingomyelin synthase 2 and can be used for treating diseases caused by abnormally increased sphingomyelin level. The invention further provides application of the compound, the pharmaceutically acceptable salt thereof or the pharmaceutical composition taking the compound as an effective active ingredient in the preparation of medicines for preventing and treating diseases caused by abnormal increase of sphingomyelin level, including atherosclerosis, type II diabetes, fatty liver and obesity, metabolic syndrome thereof and inflammatory diseases including enteritis.

Using NMR / MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and / or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.

Compositions and methods relating to modulating thermogenic regulation are disclosed. The compositions and methods can be used to treat diseases or conditions such as obesity or cardiometabolic disorders such as type 2 diabetes mellitus, NAFLD and NASH. Compositions include an adipocyte-targeting composition that includes a therapeutic agent capable of modulating thermogenic regulation, a targeting element facilitating cellular uptake and delivery of the therapeutic agent to a targeted adipocyte, and liposomal particles comprising sphingomyelin, DMPC, and cholesterol, wherein the liposomal particles enhance intra-cellular penetration of the therapeutic agent and protect the therapeutic agent from degradation.

A method, and associated kit, for assaying the activity of lysosomal enzymes present in dried bodily fluids and cell tissue samples, such as α-L-iduronidase, β-D-galactosidase, β-D-glucosidase, chitotriosidase, total α-D-galactosidase and α-D-galactosidase A, hexosaminidase A and B, α-D-mannosidase, β-D-mannosidase, α-L-fucosidase, N-acetyl-α-galactosaminidase, arylsulfatases, sphingomyelinase, β-galactocerebrosidase, iduronate-2-sulfatase and β-D-glucuronidase. The method includes: (a) combining with a dried bodily fluid or cell tissue sample containing at least one type of lysosomal enzyme: (1) an eluent, (2) an incubation buffer and (3) a substrate or substrates capable of reacting with the assayed lysosomal enzymes and producing their corresponding enzyme product or products, (b) allowing the dried bodily fluid or cell tissue sample to react with the eluent, incubation buffer and substrate or substrates for an adequate time and temperature, and (c) applying measuring means to the enzyme product to determine the activities of the lysosomal enzymes present.

A nutritional composition having a total energy content of 67 kcal / 100 ml or lower and including: a protein content which is 1.25 g / 100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg / 100 ml, a cholesterol content of 5-10 mg / 100 ml, and a sphingomyelin content of 9-15 mg / 100 ml is disclosed.

The present invention relates to the technical field of cosmetics, in particular to a liposome structure, composition and preparation method for skin cleaning and anti-aging, which consists of two liposomes A and B with different structures in a weight ratio of 1:1; Wherein, the liposome A is a multilayer liposome structure, which is formed by wrapping the skin cleansing composition with a wall material, and the composition of the liposome A wall material is lecithin and soybean lecithin; the liposome B is a single-layer liposome The lipid vesicle structure is formed by wrapping the skin anti-aging composition with the wall material, and the components of the liposome B wall material are sphingomyelin, cholesterol, fatty acid, phosphatidylcholine and cholesterol sulfate. The present invention adopts liposome A and microliposome B with two different particle sizes and structures to wrap the skin cleansing composition and the skin anti-aging composition respectively, and acts on the skin surface and deep layer of the skin respectively. The mutual synergy and mutual promotion can achieve significant skin cleansing and anti-aging effects.

Use of an α-lactalbumin enriched whey protein extract as a source of sphingomyelin in a synthetic nutritional composition for an infant or child wherein, the α-lactalbumin enriched WPE is obtained by a process comprising: a. acidifying a whey protein product to pH 4 or below b. forming a low calcium whey protein product by concentrating the proteins in the acidified whey protein until the calcium to protein ratio is less than about 0.001 and, c. Precipitating α-lactalbumin from the low-calcium whey protein product, wherein said precipitating step includes the sub-steps of: I. diluting the low-calcium whey protein product, II. adjusting the pH of the diluted low-calcium whey protein product to between 4 and 5 to form a precipitate and soluble proteins, and III. Separating the precipitate proteins from the soluble proteins.

Novel cyclic and acyclic oxazaphospholanes are described, as well as their use in the synthesis of sphingomyelin and sphingomyelin analogous. The production of synthetic sphingomyelins is also described. 2S, 3R stereoisomers of oxazaphospholanes and sphingomyelins, and synthetic methods for their preparation are described.

The invention discloses a compound used in the diagnosis of polycystic ovary syndrome. The compound is one of androsterone glucuronide or sphingomyelin (d17:1 / 24:1), or the compound is Combination of androstone glucuronide with sphingomyelin (d17:1 / 24:1). The beneficial effect of the present invention is that the non-target metabolomics research of polycystic ovary syndrome urine is carried out by ultra-high pressure liquid phase tandem time-of-flight mass spectrometry, and androsterone glucuronide, sphingomyelin lipid (d17:1 / 24: 1) and their combination have better diagnostic value for polycystic ovary syndrome. The purpose of simple and rapid diagnosis of polycystic ovary syndrome is achieved, and the detection cost is reduced at the same time.

Disclosed are: a sense-improving agent which comprises, as an active ingredient, a phospholipid or a sphingosine-containing phospholipid and / or a derivative thereof, particularly a sphingomyelin, and which has an effect of improving the dulling of senses at a periphery when ingested orally or directly applied to the skin; and a sense-improving food, beverage, feed or cosmetic comprising the sense-improving agent. The phospholipid to be used may be a chemically synthesized phospholipid or a naturally occurring phospholipid, preferably a phospholipid derived from an edible material such as soybean and egg yolk, particularly preferably a phospholipid derived from milk.